title: Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.
abstract: Laninamivir octanoate hydrate (laninamivir) is a long-acting neuraminidase inhibitor which requires only a single inhaled dose to fully treat infection by the influenza virus. In Japan, this drug was launched in October 2010 as a new treatment for the influenza virus. A postmarketing surveillance study was conducted in the 2010/2011 influenza season to assess the efficacy of this drug in clinical settings. For 3542 patients evaluated for efficacy (type A, n = 3179; type B, n = 342, unknown type, n = 3), including the day of drug administration, the median duration to fever resolution was three days, and the median duration to relief from influenza symptoms was four days. Based on the judgment of participating physicians, the efficacy rate was 97.6 % for type A influenza, 93.3 % for type B influenza, and 100 % in unknown types. "Treatment failure," as judged by participating physicians, was most closely correlated with the inhalation status of laninamivir. Despite laninamivir requiring only the administration of a single dose, it was confirmed to be an effective treatment in more than 90 % of patients with type A or type B influenza virus infections. This drug was considered to be useful for the treatment of influenza infections due to ease of use and its improvement of compliance. It became clear that the efficacy of laninamivir depended strongly on the status of inhalation, and thus careful and detailed instructions on the correct method of inhalation were considered to be important in order to obtain reliable therapeutic effects.
authors.affiliation: Kashiwagi Clinic, Hakata Station Area Business Center 1F, 3-25-21 Hakataekimae, Hakata-ku, Fukuoka, Japan. Kashiwagi@daido-g.jp
authors.forename: Seizaburo
authors.initials: S
authors.lastname: Kashiwagi
authors.forename: Sanae
authors.initials: S
authors.lastname: Yoshida
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yamaguchi
authors.forename: Noriko
authors.initials: N
authors.lastname: Mitsui
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Tanigawa
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Shiosakai
authors.forename: Naoki
authors.initials: N
authors.lastname: Yamanouchi
authors.forename: Tomoo
authors.initials: T
authors.lastname: Shiozawa
authors.forename: Fumie
authors.initials: F
authors.lastname: Yamaguchi
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D005334:Fever / Q000188:drug therapy / Q000821:virology; D006146:Guanidines; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy* / Q000201:enzymology / Q000453:epidemiology; D007564:Japan / Q000453:epidemiology; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D011358:Product Surveillance, Postmarketing / Q000706:statistics & numerical data*; D011714:Pyrans; D012794:Sialic Acids; D016896:Treatment Outcome; D053243:Zanamivir / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; C546918:laninamivir; D009439:Neuraminidase; D053243:Zanamivir